Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women

被引:110
作者
Lazo, Mariana
Gange, Stephen J.
Wilson, Tracey E.
Anastos, Kathryn
Ostrow, David G.
Witt, Mallory D.
Jacobson, Lisa P.
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] SUNY Hlth Sci Ctr, Brooklyn, NY USA
[3] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA
[4] Montefiore Med Ctr, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
[5] David Ostrow & Assoc, Lakewood, IL USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Torrance, CA 90509 USA
[7] Harbor UCLA Med Ctr, Los Angeles Biomed Gen Clin Res Ctr, Torrance, CA 90509 USA
关键词
D O I
10.1086/522762
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Adherence to therapy is a dynamic behavior. However, few studies have identified factors associated with changes in adherence to highly active antiretroviral therapy (HAART) among men and women. Methods. From 1999 through 2004, self-reported adherence to HAART was recorded twice yearly as part of 2 prospective cohort studies. At each study visit, participants were categorized as being 100% adherent if they reported full adherence with their HAART regimen over the past 4 days (for men) and 3 days (for women). Repeated-measures logistic regression models were used to identify predictors for changes in adherence between consecutive visits. Results. Of the participants, 640 men and 1304 women contributed 2803 and 5972 visit-pairs, respectively. Among white men, the prevalence of 100% adherence decreased from 91% in 1998 to 80% in 2003. Among women and African American men, the prevalence of full adherence was lower (75% and 77% on average, respectively) and stable over time (P >.6 ). In both cohorts, the presence of clinical symptoms was independently associated with decreasing adherence (odds ratio [OR], 1.38 in men and 1.48 in women). Depression in men (OR, 1.44) and use of alcohol in women (OR, 1.81, 1.52, and 1.29, for binge drinking, moderate-to-heavy drinking, and low consumption, respectively) also predicted decreasing adherence. In addition, the use of drugs by men and women (OR, 0.61 and 0.58, respectively) and alcohol binging by women (OR, 0.41) were negatively associated with improving adherence. Conclusions. Adherence to antiretroviral treatment is a dynamic process; modifiable risk factors are associated with increasing and decreasing adherence, suggesting specific interventions. Moreover, the association of these risk factors with changes in adherence may differ by sex.
引用
收藏
页码:1377 / 1385
页数:9
相关论文
共 42 条
[21]   THE MULTICENTER AIDS COHORT STUDY - RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTS [J].
KASLOW, RA ;
OSTROW, DG ;
DETELS, R ;
PHAIR, JP ;
POLK, BF ;
RINALDO, CR .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1987, 126 (02) :310-318
[22]   Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study [J].
Kleeberger, CA ;
Buechner, J ;
Palella, F ;
Detels, R ;
Riddler, S ;
Godfrey, R ;
Jacobson, LP .
AIDS, 2004, 18 (04) :683-688
[23]  
Kleeberger CA, 2001, J ACQ IMMUN DEF SYND, V26, P82, DOI 10.1097/00126334-200101010-00012
[24]   Interval and clinical cohort studies: Epidemiological issues [J].
Lau, Bryan ;
Gange, Stephen J. ;
Moore, Richard D. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (06) :769-776
[25]  
Li XH, 2005, JAIDS-J ACQ IMM DEF, V38, P320
[26]   Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic [J].
Lucas, GM ;
Gebo, KA ;
Chaisson, RE ;
Moore, RD .
AIDS, 2002, 16 (05) :767-774
[27]   Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors [J].
Maggiolo, F ;
Ravasio, L ;
Ripamonti, D ;
Gregis, G ;
Quinzan, G ;
Arici, C ;
Airoldi, M ;
Suter, F .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (01) :158-163
[28]   The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials [J].
Mannheimer, S ;
Friedland, G ;
Matts, J ;
Child, C ;
Chesney, M .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1115-1121
[29]   Adherence to antiretroviral therapy in sub-Saharan Africa and North America - A meta-analysis [J].
Mills, Edward J. ;
Nachega, Jean B. ;
Buchan, Iain ;
Orbinski, James ;
Attaran, Amir ;
Singh, Sonal ;
Rachlis, Beth ;
Wu, Ping ;
Cooper, Curtis ;
Thabane, Lehana ;
Wilson, Kumanan ;
Guyatt, Gordon H. ;
Bangsberg, David R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (06) :679-690
[30]   Injection drug use and patterns of highly active antiretroviral therapy use: An analysis of ALIVE, WIHS, and MACS cohorts [J].
Morris J.D. ;
Golub E.T. ;
Mehta S.H. ;
Jacobson L.P. ;
Gange S.J. .
AIDS Research and Therapy, 4 (1)